XTalks

JULY 28, 2020

These data illustrate that while many excipient molecules are in fact inert, a good number may have previously unappreciated effects on human proteins known to play an important role in health and disease,” Shoichet said. But just how inert are these excipients?

Protein 103

Protein Drugs In-Vitro Scientist 103

pharmaphorum

JANUARY 16, 2023

There were developments in the past 12 months, true – Biogen/Eisai’s lecanemab (now branded Leqembi) showed clear success in the Clarity AD trial and received approval by FDA on 6th January 2023. This is linked to wider questions about the role damaged proteins and their build up plays in ageing across different tissues and organs.

Gene Therapy 98

Gene Therapy In-Vitro Gene Medicine 98

The Pharma Data

APRIL 29, 2022

About Evrysdi® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Evrysdi is designed to treat SMA by increasing and sustaining the production of the SMN protein in the central nervous system (CNS) and peripheral tissues.

Protein 52

Protein In-Vitro Medicine Development 52

Druggist

FEBRUARY 17, 2021

Most pharmacies sell hydrocortisone cream as ‘own’ label product or branded products, foe example HC45 Hydrocortisone cream. For many customers, ointment or cream for insect bites is the first line of rescue in stings management. I will also discuss alternative options for insect bites, mainly the use of antihistamines.

Pharmacy 98

Pharmacy Containment Production Sales 98

The Pharma Data

JANUARY 31, 2021

Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled proteins (GPCRs). Ion channels are a class of integral membrane proteins that regulate the flow of ions across the cell membrane as a means of conducting signals between cells and their environment.

Drugs 52

Drugs Protein In-Vitro Development 52

The Pharma Data

MARCH 20, 2023

Data confirm increases in motor function were sustained at four years and the overall rate of adverse events continued to decrease over the 48 month period, reinforcing the long-term efficacy and safety of Evrysdi. Without treatment, natural history data show that patients with Type 2 or 3 SMA typically show a decline in motor function over time.

Protein 40

Protein In-Vitro Medicine Trials 40

The Pharma Data

MAY 4, 2021

Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 Billion and Adjusted Diluted EPS (2) to a Range of $3.55 Now Anticipates Revenues of Approximately $26 Billion for BNT162b2, Reflecting 1.6 Billion Doses Expected to be Delivered in 2021 Under Signed Contracts as of Mid-April 2021. per share amounts). Reported Diluted EPS (1).

Vaccination 40

Vaccination Vaccine Production Sales 40

The Pharma Data

MAY 14, 2021

It looked like a hurricane had pummeled through my closet…. Wrinkled jeans and dresses scattered in every direction…. There wasn’t a single outfit that fit me…. I swear — I went to bed a size 10 and woke up a size 16. My teenage daughter shouted at me from downstairs for the third time…. I have to be at school in 5 minutes!”. What are you doing?!

Hormones 52

Hormones Production Doctors Doctor 52

XTalks

SEPTEMBER 14, 2020

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92